Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Yigal Nochomovitz - Citi Brian Cheng - JPMorgan Jonathan Miller - Evercore ISI Jay Olson - Oppenheimer & Co. Justin Zelin - BTIG Operator Thank you for standing by. This is the conference operator.
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago.
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks should start generating royalties on net sales this quarter. The phase 3 results for Ziihera in first-line GEA patients are now expected in Q2 2025, and represent the next critical step for Zymeworks and its partner Jazz.
Zymeworks upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Zymeworks to Overweight from Neutral with an $18 price target.
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
The PDUFA date for potential approval of Zanidatamab for the treatment of patients with 2nd-line biliary tract cancer set for November 29th of 2024. Progression-free survival data from the phase 3 HERIZON-GEA-01 study using Zanidatamab + chemotherapy plus or minus tislelizumab for treatment of patients with 1st-line GEA is expected in Q2 of 2025. Zanidatamab is being developed in collaboration with two big pharmaceutical companies, which are Jazz Pharmaceuticals and BeiGene.
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President, Chief Business and Financial Officer Paul Moore - Chief Scientific Officer Kenneth Galbraith - Chair and Chief executive Officer Conference Call Participants Stephen Willey - Stifel Ashiq Mubarack - Citi Brian Cheng - JPMorgan Jon Miller - Evercore ISI Derek Achila - Wells Fargo Operator Hello. Thank you for standing by.
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.41 per share a year ago.
Zymeworks Approaching A Moment Of Truth With Zanidatamab
ZYME's zanidatamab is under regulatory review for the treatment of second-line HER2-positive biliary tract cancer, with potential US approval in November 2024. Subsequent approval in the same indication could follow in the EU as early as Q2 '25, and in China in H2 '25. A readout from the HERIZON-GEA-01 study of zanidatamab in gastroesophageal adenocarcinoma in Q2 '25 represents a major clinical catalyst for ZYME.
Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Bijal Desai - Vice President-Finance & Strategy Paul Moore - Chief Scientific Officer Ken Galbraith - Chair & Chief Executive Officer Pranshul Chauhan - Associate Medical Director Conference Call Participants Stephen Willey - Stifel Jon Miller - Evercore Robert Burns - H.C. Wainwright Operator Thank you for standing by.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.76 per share a year ago.
Zymeworks Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ZYME
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.
Levi & Korsinsky Reminds Zymeworks Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ZYME
NEW YORK, NY / ACCESSWIRE / May 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.
